• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

69.27 -2.53 (-3.52%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 142,399
Open 71.01
Bid (Size) 46.69 (100)
Ask (Size) 111.00 (100)
Prev. Close 71.80
Today's Range 68.81 - 71.01
52wk Range 50.07 - 124.82
Shares Outstanding 14,157,941
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
August 19, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 12, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire

Performance

52-Week Range 44.5% below 52-week high
69.27
50.0752W Low 124.8252W High
1 Week 17.6% below 1-week high
70.051W Low 84.041W High

Monopar Therapeutics Inc. - Common Stock (MNPR) traded between $50.07 and $124.82 over the past 52 weeks and last traded at $69.27, 44.5% below its 52-week high. Over the past week it ranged between $70.05 and $84.04.

Past 12 Months
-12.3%
-33.6%
-36.2%
+20.1%
+4.9%
-23.4%
1W -$9.69
1M -$35.06
3M -$39.25
6M +$11.57
YTD +$3.26
1Y -$21.15

MNPR was -23.4% over the past year, +20.1% over six months, +4.9% year to date, -12.3% in the last week.

12 Months vs Market
MNPR
-23.4%
DIA
+12.2%
SPY
+14.7%
QQQ
+17.9%
IWM
+8.0%

Over the past 12 months MNPR returned -23.4% versus DIA (Dow) +12.2%, SPY (S&P 500) +14.7%, QQQ (Nasdaq 100) +17.9% and IWM (Russell 2000) +8.0%.

Volume & Liquidity 0.69× 3-mo avg
Today 142,399 3-mo avg 205.8K
1W
155.2K
1M
166.9K
3M
205.8K
6M
192.2K
YTD
209.1K
1Y
204.2K

MNPR most recently traded 142,399 shares against a 3-month average daily volume of 205.8K.

More News

Read More
News headline image
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
July 22, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
July 20, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
June 30, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
June 26, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
June 01, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
May 19, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 14, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
April 19, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
March 27, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
March 02, 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
November 14, 2025
Via Benzinga
News headline image
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
November 13, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
November 09, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
October 15, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
October 13, 2025
Via Benzinga
News headline image
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗
September 25, 2025
Via Benzinga
News headline image
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
September 23, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
September 23, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout ↗
September 15, 2025
Via Investor's Business Daily
News headline image
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
September 03, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
September 14, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
August 12, 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Monopar Therapeutics Inc. - Common Stock publicly traded?
Yes, Monopar Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Monopar Therapeutics Inc. - Common Stock trade on?
Monopar Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Monopar Therapeutics Inc. - Common Stock?
The ticker symbol for Monopar Therapeutics Inc. - Common Stock is MNPR on the Nasdaq Stock Market
What is the current price of Monopar Therapeutics Inc. - Common Stock?
The current price of Monopar Therapeutics Inc. - Common Stock is 69.27
When was Monopar Therapeutics Inc. - Common Stock last traded?
The last trade of Monopar Therapeutics Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Monopar Therapeutics Inc. - Common Stock?
The market capitalization of Monopar Therapeutics Inc. - Common Stock is 980.72M
How many shares of Monopar Therapeutics Inc. - Common Stock are outstanding?
Monopar Therapeutics Inc. - Common Stock has 981M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap